Redwire (NYSE: RDW) announced that its SpaceMD platform has selected SpaceX's Starfall spacecraft for its first commercial mission, scheduled for 2028. The mission aims to advance in-space pharmaceutical research and manufacturing by leveraging the unique microgravity environment to accelerate drug development and scale space-based biopharmaceutical production. Sector: Space Technology / Biotechnology Key Highlights 🚀 SpaceMD selected SpaceX's Starfall spacecraft for its first commercial mission 💊 Mission scheduled for 2028 to advance pharmaceutical research in microgravity 🧬 Focused on scaling space-based drug development and manufacturing 🌌 Utilizes the benefits of the microgravity environment for biopharma innovation 🤝 Strengthens Redwire's position in the emerging space biotechnology market Why It Matters The mission marks a significant step in commercializing in-space pharmaceutical manufacturing, positioning Redwire to capitalize on the growing intersection of biotechnology and space innovation. Read More: https://www.thinksabio.com/reports/isr/RDW